Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06898515). This is a study registration, not published results. Lead sponsor: Reprieve Cardiovascular, Inc. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 400 participants (ESTIMATED). Conditions: Acute Decompensated Heart Failure. Interventions: DEVICE: Reprieve System; DRUG: furosemide infusion. Primary outcome measures: Hierarchical composite/win-ratio , 1. up to 30 days from randomization, 2. up to 30 days from discharge, 3. up to 72 hours after randomization; Incidence of device/procedure-related adverse events (KDIGO stage 2 or greater AKI, CAUTI) , initiation of randomized therapy through 72 hours following completion of randomized therapy. Brief summary: The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more efficiently decongest ADHF patients in comparison to Control Therapy.